Karyopharm Therapeutics Inc

NASDAQ:KPTI   3:59:59 PM EDT
16.99
+1.85 (+12.22%)
Products, Regulatory

Karyopharm Says Late-Stage Data Shows Treatment With Xpovio Reduced Risk Of Disease Progression Or Death By About 30%

Published: 11/20/2020 16:26 GMT
Karyopharm Therapeutics Inc (KPTI) - Karyopharm Reports Positive Phase 3 Seal Data in Oral Presentation at the Connective Tissue Oncology Society 2020 Annual Meeting.
Karyopharm Therapeutics Inc - Look Forward to Submitting a New Drug Application to U.S. Food and Drug Administration During Q1 of 2021.
Karyopharm Therapeutics - Data Indicate Treatment With Xpovio Reduced Risk of Disease Progression Or Death by About 30%, Compared to Placebo.